Aim of this randomized, double-blind clinical study is to evaluate the efficacy of a nutraceutical preparation on early markers of cognitive impairment, in patients affected by arterial hypertension.

Inclusion Criteria:

• Written informed consent;
• Males or females between 40 and 65 years of age;
• Hypertensive patients classified according to their SBP (Systolic Blood Pressure) and DBP (Diastolic Blood Pressure) values. Included patients will be those with stage 1 hypertension (SBP 140-159 mmHg; DBP 90-99 mmHg) and with stage 2 hypertension (SBP 160-179 mmHg; DBP 100-109 mmHg).

Exclusion Criteria:

• Previous acute myocardial infarction (AMI);
• Previous stroke and/or transient ischemic attack (TIA);
• Diabetes mellitus;
• History of atrial fibrillation or other severe arrhythmias;
• Severe cardiovascular diseases;
• Renal pathologies (creatinine > 1.4 mg/dL);
• Preexisting psychiatric pathologies;
• Neurodegenerative diseases, such as multiple sclerosis, lateral amyotrophic sclerosis, Parkinson, Alzheimer, neuromuscular pathologies, epilepsy;
• Diagnosis of dementia;
• Depression;
• Long-term regular use of anxiolytics drugs, antidepressant drugs, antipsychotic drugs, hypnoinducing drugs, cognitive stimulators.